phd1  (Proteintech)

Journal: The Journal of Gene Medicine

Article Title: YAP1 Overexpression Enhances the Aerobic Glycolysis Process via Suppression of EGLN2 in Pancreatic Ductal Adenocarcinoma

doi: 10.1002/jgm.70006

Figure Lengend Snippet: Decreased EGNL2 expression predicted poor survival and was negatively correlated with YAP1 expression in pancreatic cancer patients. (A–C) The prognostic value of EGLN family members, including EGLN1, EGLN2 and EGLN3, was demonstrated by analysis of the TCGA dataset, which revealed that decreased expression of EGLN2 predicted a poor prognosis in patients with pancreatic cancer. (D–F) Correlation analysis of the TCGA dataset revealed that YAP1 expression was negatively correlated with EGLN2, whereas no significant correlations between YAP1 expression and EGLN1 or EGLN3 expression were detected.

Article Snippet: Antibodies against β‐actin, HK2, GLUT1, HIF‐1α, EGLN2 and YAP1 were manufactured by Proteintech.

Techniques: Expressing

Journal: The Journal of Gene Medicine

Article Title: YAP1 Overexpression Enhances the Aerobic Glycolysis Process via Suppression of EGLN2 in Pancreatic Ductal Adenocarcinoma

doi: 10.1002/jgm.70006

Figure Lengend Snippet: YAP expression was negatively correlated with EGLN2 expression in pancreatic cancer tissue samples. (A) We examined the transcriptional levels of ELGN1, EGLN2 and EGLN3 in YAP1‐silenced PANC‐1 and MIA PaCa‐2 cells and found that YAP1 silencing significantly increased EGLN2 expression. (B) Consistent with the transcription results, EGLN2 protein expression was increased in YAP1‐knockdown PANC‐1 and MIA PaCa‐2 cells. (C) IHC staining revealed that the EGLN2 level was low in patients who expressed high levels of YAP1 (magnification scale bar, 200 μm; scale bar in the enlarged image, 40 μm). (D) The number of tissue samples used for YAP1 and EGLN2 IHC staining. The data are presented as the mean ± SD. Statistical analysis was performed via the two‐tailed Student's t ‐test.

Article Snippet: Antibodies against β‐actin, HK2, GLUT1, HIF‐1α, EGLN2 and YAP1 were manufactured by Proteintech.

Techniques: Expressing, Knockdown, Immunohistochemistry, Two Tailed Test

Journal: The Journal of Gene Medicine

Article Title: YAP1 Overexpression Enhances the Aerobic Glycolysis Process via Suppression of EGLN2 in Pancreatic Ductal Adenocarcinoma

doi: 10.1002/jgm.70006

Figure Lengend Snippet: EGLN2 is a direct downstream target of YAP1. (A) We cloned the promoter region of EGLN2, ranging from −2000 to +200, into the pGL3‐Basic vector, and observed that YAP1 inhibited EGLN2 promoter activity in a dose‐dependent manner. (B) Schematic representation of the ELGN2 promoter region showing that the EGLN2 promoter region contains five putative TEAD sites. (C) The sequence of the five TSs. (D) A ChIP assay with an anti‐YAP1 antibody demonstrated that YAP1 occupied the promoter region which contains TSs. (E) A ChIP‐qPCR assay further confirmed that YAP1 occupied the genomic region of the EGLN2 promoter. (F) A working model illustrating the role of YAP1 in aerobic glycolysis control. The data are presented as the mean ± SD. Statistical analysis was performed via the two‐tailed Student's t ‐test.

Article Snippet: Antibodies against β‐actin, HK2, GLUT1, HIF‐1α, EGLN2 and YAP1 were manufactured by Proteintech.

Techniques: Clone Assay, Plasmid Preparation, Activity Assay, Sequencing, ChIP-qPCR, Control, Two Tailed Test